trending Market Intelligence /marketintelligence/en/news-insights/trending/nOHegqD_o4ZuHyy9c-vuow2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Biom'Up raises €38.1M in IPO to fund blood clotting products

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biom'Up raises €38.1M in IPO to fund blood clotting products

Biom'Up said it raised €38.1 million in an initial public offering on the Euronext Exchange following strong demand from French, U.K. and U.S. investors.

The French medical company, which develops products to stop bleeding during surgery, priced its shares at €10.5 apiece for a market capitalization of €113 million.

Biom'Up intends to use the proceeds partly to prepare for the U.S. launch of its Hemoblast Bellows product, which helps blood coagulate during surgery.

The product is under review at the U.S. Food and Drug Administration with a decision expected in mid-2018.

Biom'Up shares will be admitted to the Euronext Exchange and start trading Oct. 13.

The company is the first healthcare group to IPO on the exchange in six months.